An observational study in Psoriasis, sponsored by Genentech, Inc.. Completed at 182 sites in United States. Per ClinicalTrials.gov, last updated 2015-07-02.
Sponsored by Genentech, Inc. · Observational
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 1,846 is above the median of 200 across 396 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Genentech, Inc. is the lead sponsor of 507 studies on the registry; 23 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 50 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
managed care organizations, community or physician practices, and academic centers in the United States
Exclusion Criterion:
Showing the first 100 of 182 sites.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genentech, Inc.